On October 7, 2024, Patrick Smith, President of Drug Development Solutions at Certara Inc (CERT, Financial), sold 5,409 shares of the company. The transaction was filed on October 8, 2024, as reported in the SEC Filing. Following this sale, the insider now owns 50,091 shares of Certara Inc.
Certara Inc specializes in providing software and scientific consulting services, including modeling and simulation for drug development. The company supports decisions made by regulatory agencies and pharmaceutical companies regarding drug approvals and clinical trials.
Over the past year, Patrick Smith has sold a total of 24,836 shares of Certara Inc and has not purchased any shares. This recent transaction is part of a broader trend where there have been 7 insider sells and no insider buys over the past year at Certara Inc.
Shares of Certara Inc were trading at $11.03 on the day of the sale. The company has a market cap of approximately $1.808 billion.
The stock's valuation metrics show a GF Value of $19.91, indicating a price-to-GF-Value ratio of 0.55. This suggests that the stock might be a possible value trap, and investors should think twice before investing, based on its GF Value.
The GF Value is calculated considering historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
This insider sale might provide valuable insights for current and potential investors into the insider's view of the stock's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
